Pain Relievers and Stomach Safety

Pain relievers and stomach safety is a topic with significant real-world consequences: NSAIDs (non-steroidal anti-inflammatory drugs) are among the most widely used medications worldwide, yet they carry a well-documented risk of gastrointestinal damage that is responsible for tens of thousands of hospitalizations annually. The challenge is that GI side effects from NSAIDs rarely announce themselves with obvious warning symptoms — many patients who develop a peptic ulcer or upper GI bleed from NSAID use had no preceding pain or discomfort that would have prompted them to stop the medication. Understanding how NSAIDs damage the stomach, who is at highest risk, and how to manage pain effectively while protecting the GI mucosa is practical knowledge for anyone who takes these medications regularly or in high doses.

This article covers how NSAIDs and other pain relievers affect the stomach and upper GI tract, risk stratification for NSAID-related GI complications, the role of gastroprotection with proton pump inhibitors, and when paracetamol (acetaminophen) or alternative pain management strategies are preferable. For the broader context of how medications affect the digestive system, see the article on digestive medications for adults. The properties and safety profile of proton pump inhibitors used for gastroprotection are covered in detail in the proton pump inhibitors article.

How NSAIDs Damage the Stomach

NSAIDs cause gastrointestinal damage through two distinct mechanisms, both of which are related to their inhibition of cyclooxygenase (COX) enzymes. COX enzymes produce prostaglandins — signalling molecules that perform multiple physiological functions throughout the body. In the stomach, prostaglandins are particularly important: they stimulate the secretion of the thick mucous layer that protects the gastric epithelium from the highly acidic gastric contents, stimulate bicarbonate secretion that neutralises acid at the mucosal surface, maintain mucosal blood flow, and promote epithelial cell renewal. When NSAIDs inhibit COX enzymes and reduce prostaglandin production, these protective mechanisms are compromised — the stomach’s defences against its own acid are weakened, allowing acid to damage the epithelium.

The first mechanism is systemic: even NSAIDs administered by routes that bypass the stomach (suppositories, injections, transdermal patches) cause significant GI mucosal injury because the prostaglandin suppression is systemic — the reduction in mucosal protective prostaglandins occurs throughout the GI tract regardless of where the drug was administered. This is an important point that is often misunderstood: taking enteric-coated NSAIDs or administering them by non-oral routes reduces direct local irritation but does not prevent the systemic prostaglandin-mediated mucosal damage.

The second mechanism is direct local toxicity: NSAIDs are weak acids that accumulate in the acidic environment of the stomach, where they become non-ionised and can penetrate gastric epithelial cells, disrupting cellular membranes and causing direct epithelial cell damage. This direct local effect is responsible for the irritation and dyspepsia many patients experience with oral NSAIDs, and it is this component — though not the systemic component — that can be reduced by enteric coating or taking the medication with food.

Risk Factors for NSAID-Related GI Complications

Not all NSAID users are at equal risk of GI complications. Clinical risk stratification guides the decision about whether to add gastroprotective therapy and influences the choice between conventional NSAIDs, selective COX-2 inhibitors (coxibs), or alternative analgesic strategies:

• Prior GI ulcer or GI bleed: The single strongest risk factor. Patients with a history of peptic ulcer disease or upper GI bleeding have a 4- to 5-fold higher risk of recurrence when taking NSAIDs compared to patients with no prior history.
• Age ≥65: GI mucosal defence mechanisms decline with age, and the consequences of GI bleeding are more severe in older adults due to reduced physiological reserve and more complex comorbidities.
• Concomitant anticoagulant use: Taking an NSAID with warfarin, a direct oral anticoagulant (DOAC), or heparin dramatically increases the risk of clinically significant GI bleeding — not because NSAIDs cause more ulcers in anticoagulated patients, but because any NSAID-related mucosal erosion is much more likely to bleed significantly when coagulation is impaired.
• Concurrent corticosteroid use: Corticosteroids alone have a relatively low GI ulceration risk, but in combination with NSAIDs the risk of peptic ulceration is multiplicative rather than additive — some studies put the combined risk at 15-fold higher than either drug alone.
• H. pylori infection: Helicobacter pylori and NSAID use have a synergistic effect on ulcer risk. Patients who are H. pylori positive and use NSAIDs have substantially higher ulcer rates than either risk factor alone would predict.
• High NSAID dose or prolonged use: Higher doses and longer durations of use are linearly associated with increasing GI risk. The GI risk of aspirin, despite its low analgesic dose, is dose-dependent — even low-dose aspirin (75–150 mg) used for cardiovascular prophylaxis carries measurable GI mucosal risk.
• Multiple NSAIDs simultaneously: Combining two NSAIDs (including low-dose aspirin plus a full-dose NSAID) significantly increases GI risk compared to either drug alone.

COX-2 Selective Inhibitors: A Safer GI Option?

The recognition that prostaglandin-mediated gastroprotection is primarily mediated by the COX-1 isoform, while inflammation and pain signals are primarily mediated by the COX-2 isoform, led to the development of COX-2 selective inhibitors (coxibs) — NSAIDs designed to inhibit COX-2 preferentially while sparing COX-1, thereby reducing GI mucosal damage while maintaining anti-inflammatory efficacy. The major coxibs in current clinical use are celecoxib (the most widely used) and etoricoxib.

The clinical evidence supports a meaningful GI safety advantage for COX-2 selective inhibitors compared to non-selective NSAIDs: multiple large randomised trials (the CLASS trial for celecoxib, the MEDAL programme for etoricoxib) have demonstrated significantly lower rates of symptomatic ulcers and ulcer complications. However, the advantage is substantially reduced or eliminated in patients taking low-dose aspirin concurrently — aspirin’s non-selective COX inhibition overrides the gastroprotective benefit of COX-2 selectivity. This is relevant because many patients who would benefit from COX-2 selective NSAIDs (older adults with arthritis and cardiovascular risk) are also taking aspirin for cardiovascular prophylaxis.

The cardiovascular risk profile of coxibs is an important counterbalancing consideration: the withdrawal of rofecoxib (Vioxx) in 2004 due to increased cardiovascular event rates established that selective COX-2 inhibition is associated with increased thrombotic risk — a finding that has modulated enthusiasm for coxibs. Celecoxib and etoricoxib carry a cardiovascular risk warning and are not recommended for patients with established cardiovascular disease.

Paracetamol: A Stomach-Safe Alternative With Its Own Risks

Paracetamol (acetaminophen) does not inhibit COX enzymes in peripheral tissues at therapeutic doses and does not cause the prostaglandin-mediated gastric mucosal damage associated with NSAIDs. It is therefore the recommended first-line analgesic for mild to moderate pain in patients at high risk of GI complications, in older adults, and in patients for whom NSAID GI risk outweighs the anti-inflammatory benefit. Paracetamol has no significant direct GI mucosal toxicity and does not increase the risk of peptic ulceration.

This does not make paracetamol risk-free. Its hepatotoxicity profile is well established: acute overdose causes severe liver damage through accumulation of the toxic metabolite NAPQI (N-acetyl-p-benzoquinone imine), and even therapeutic dose paracetamol in patients with heavy alcohol use or pre-existing liver disease can cause significant hepatic injury. The maximum recommended dose of 4 grams per day (1 gram four times daily) should not be exceeded, and lower doses (2–3 grams per day) are appropriate for patients who drink regularly, have liver disease, or are elderly. Liver safety and medication use are examined in detail in the companion article on liver safety and medications.

Paracetamol’s anti-inflammatory activity is substantially weaker than that of NSAIDs, which matters for conditions where inflammation is a major component of pain — inflammatory arthritis, gout, acute musculoskeletal injuries. In these situations, the stomach-safer choice (paracetamol) may not be the therapeutically effective choice, and the clinical decision becomes a risk-benefit assessment: is the anti-inflammatory efficacy of an NSAID necessary, and if so, how can GI risk be mitigated?

Gastroprotection Strategies When NSAIDs Are Necessary

For patients who need NSAIDs and are at moderate to high GI risk, co-prescription of a proton pump inhibitor (PPI) is the most effective gastroprotective strategy, reducing the risk of symptomatic NSAID-related ulcers by approximately 80% compared to NSAID use without gastroprotection. PPIs reduce gastric acid production, raising gastric pH and allowing the damaged mucosa to heal rather than face continuous acid exposure. Standard gastroprotective doses are omeprazole 20 mg, lansoprazole 15 mg, or pantoprazole 20 mg once daily. The PPI should be started at the same time as the NSAID — starting it after GI symptoms develop is reactive rather than preventive.

H2 receptor antagonists (such as famotidine or ranitidine) are less effective than PPIs for gastroprotection in NSAID users and are generally not recommended as first-line gastroprotective agents in this setting, though famotidine co-formulated with ibuprofen (available in some markets) has demonstrated benefit over ibuprofen alone in reducing peptic ulcer risk.

Testing for and eradicating H. pylori before starting long-term NSAID therapy is recommended in patients with a history of peptic ulcer disease, since H. pylori eradication significantly reduces the additional risk conferred by NSAID use. Whether H. pylori eradication alone (without continued PPI gastroprotection) is sufficient in high-risk patients is less clear — most guidelines recommend continued PPI use even after successful H. pylori eradication in patients who remain on long-term NSAIDs. The specific drugs used in H. pylori eradication and their digestive side effect profiles are relevant to the article on antibiotics and digestive side effects.

Lifestyle factors that reduce GI risk in NSAID users include using the lowest effective dose for the shortest necessary duration, always taking NSAIDs with food (which reduces direct local irritation, though not systemic mucosal damage), avoiding concurrent alcohol use (which independently injures the gastric mucosa and increases bleeding risk), and stopping smoking (smoking doubles the risk of peptic ulcer disease and impairs mucosal healing). The broader framework of digestive health behaviours and their impact on GI outcomes is covered in the article on healthy habits for liver and digestive health.

NSAID Alternatives for Patients With High GI Risk

For patients where the GI risk of NSAIDs is high enough to outweigh their benefit — or where co-prescription of a PPI is insufficient reassurance — several alternative pain management strategies deserve consideration depending on the underlying condition.

For musculoskeletal pain, topical NSAIDs (diclofenac gel, ibuprofen gel) provide anti-inflammatory effect at the target site with dramatically reduced systemic absorption. Physiotherapy, structured exercise programmes, and heat or cold therapy address underlying mechanical contributors to pain without GI risk. For osteoarthritis, intra-articular corticosteroid injections offer significant local anti-inflammatory relief with minimal systemic exposure. For neuropathic pain components — burning, shooting pain with sensory changes — gabapentin, pregabalin, tricyclic antidepressants, or duloxetine offer analgesic pathways that have no GI mucosal toxicity, though they carry their own side effect profiles.

For patients with inflammatory arthritis who genuinely require systemic anti-inflammatory treatment, disease-modifying antirheumatic drugs (DMARDs) and biologic agents address the underlying immune-mediated inflammation rather than symptom managing with NSAIDs — reducing the need for chronic NSAID use. This represents the modern approach to inflammatory arthritis management and has substantially reduced the GI complication burden compared to the era of chronic high-dose NSAID use. The relationship between physical activity, posture, and musculoskeletal pain is explored in the articles on sitting too long and digestive symptoms and stress management for gut health, which cover how activity patterns and stress physiology interact with pain and inflammation. Reviewing the full range of options available for pain management — including lifestyle interventions, physical therapies, and targeted pharmacological approaches — ensures that NSAID use is a deliberate, risk-informed choice rather than a default, and that GI protection measures are in place from the outset for any patient who genuinely needs them.

Frequently Asked Questions